In another clinical trial with locally advanced or metastatic, MET-amplified, EGFR mutation-positive NSCLC, a case of acute renal failure was found in patients treated with osimertinib plus savolitinib (55). This evidence concerns the gene EGFR and non-small cell lung carcinoma.